Correlation Between Arcus Biosciences and Mineralys Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Arcus Biosciences and Mineralys Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arcus Biosciences and Mineralys Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Arcus Biosciences and Mineralys Therapeutics, Common, you can compare the effects of market volatilities on Arcus Biosciences and Mineralys Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arcus Biosciences with a short position of Mineralys Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arcus Biosciences and Mineralys Therapeutics,.

Diversification Opportunities for Arcus Biosciences and Mineralys Therapeutics,

0.55

Correlation Coefficient

Arcus Biosciences  Mineralys Therapeutics,

Very weak diversification

The 3 months correlation between Arcus and Mineralys is 0.55. Overlapping area represents the amount of risk that can be diversified away by holding Arcus Biosciences and Mineralys Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mineralys Therapeutics, and Arcus Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arcus Biosciences are associated (or correlated) with Mineralys Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mineralys Therapeutics, has no effect on the direction of Arcus Biosciences i.e., Arcus Biosciences and Mineralys Therapeutics, go up and down completely randomly.

Pair Corralation between Arcus Biosciences and Mineralys Therapeutics,

Given the investment horizon of 90 days Arcus Biosciences is expected to generate 4.38 times less return on investment than Mineralys Therapeutics,. But when comparing it to its historical volatility, Arcus Biosciences is 1.1 times less risky than Mineralys Therapeutics,. It trades about 0.01 of its potential returns per unit of risk. Mineralys Therapeutics, Common is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  1,145  in Mineralys Therapeutics, Common on September 23, 2024 and sell it today you would earn a total of  89.00  from holding Mineralys Therapeutics, Common or generate 7.77% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Arcus Biosciences  vs.  Mineralys Therapeutics, Common

Arcus Biosciences

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Arcus Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Arcus Biosciences is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Mineralys Therapeutics,

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Mineralys Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Arcus Biosciences and Mineralys Therapeutics,

The main advantage of trading using opposite Arcus Biosciences and Mineralys Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arcus Biosciences position performs unexpectedly, Mineralys Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mineralys Therapeutics, will offset losses from the drop in Mineralys Therapeutics,'s long position.

The idea behind Arcus Biosciences and Mineralys Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.